A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
מצבים רפואיים
Neovascular Age-Related Macular Degeneration (NVAMD) · Branch Retinal Vein Occlusion (BRVO)
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
Scottsdale, Arizona, Scottsdale, Arizona, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Scottsdale, AZ, Scottsdale, Arizona, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Glendale, California, Glendale, California, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Glendale, CA, Glendale, California, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Modesto, California, Modesto, California, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Mountain View, California, Mountain View, California, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Sacramento, CA, Sacramento, California, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Sactamento, California, Sacramento, California, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Sacramento, California, Sacramento, California, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Santa Ana, California, Santa Ana, California, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Fort Lauderdale, Florida, Fort Lauderdale, Florida, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Fort Lauderdale, FL, Fort Lauderdale, Florida, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Lemont, Illinois, Lemont, Illinois, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Lemont, IL, Lemont, Illinois, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Hagerstown, Maryland, Hagerstown, Maryland, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Hagerstown, MD, Hagerstown, Maryland, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Madison, Mississippi, Madison, Mississippi, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Madison, MS, Madison, Mississippi, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Bloomfield, New Jersey, Bloomfield, New Jersey, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Bloomfield, NJ, Bloomfield, New Jersey, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Asheville, North Carolina, Asheville, North Carolina, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Cary, North Carolina, Cary, North Carolina, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Wake Forest, NC, Wake Forest, North Carolina, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Wake Forest, North Carolina, Wake Forest, North Carolina, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127West Columbia, SC, West Columbia, South Carolina, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127West Columbia, South Carolina, West Columbia, South Carolina, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Germantown, Tennessee, Germantown, Tennessee, United States
Knoxville, Tennessee, Knoxville, Tennessee, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Nashville, Tennessee, Nashville, Tennessee, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Nashville, TN, Nashville, Tennessee, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Abilene, Texas, Abilene, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Amarillo, Texas, Amarillo, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Austin, Texas, Austin, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Austin, TX, Austin, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Bellaire, Texas, Bellaire, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Bellaire, TX, Bellaire, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Burleson, Texas, Burleson, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Dallas, Texas, Dallas, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Dallas, TX, Dallas, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Plano, Texas, Plano, Texas, United States
Round Rock, TX, Round Rock, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Round Rock, Texas, Round Rock, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127San Antonio, Texas, San Antonio, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127San Antonio, TX, San Antonio, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127San Marcos, Texas, San Marcos, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127The Woodlands, Texas, The Woodlands, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127The Woodlands, TX, The Woodlands, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Willow Park, Texas, Willow Park, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127West Jordan, Utah, West Jordan, Utah, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127
מובילי המחקר
Charles Miller, MD PhD
Study Director
EyeBiotech Ltd.